At the end of the 21-28 day culture period, CD3+CD56+ cells, derived from CD3+CD56- cells, acquire cytotoxicity against various tumour cell targets, including acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), B and T-cell lymphoma. This evidence concerns the gene NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive.